Metabolic syndrome in severe mental disorders

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 2, 2011, Pages 91-98

  Ohaeri, Jude U ^a   Akanji, Abayomi O ^b  

^a Psychological Medicine Hospital Kuwait   (Kuwait)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; EATING HABIT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIC COMA; INSULIN RESISTANCE; LIFESTYLE; MENTAL DISEASE; MENTAL STRESS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; SIDE EFFECT; SMOKING; STRESS; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ENVIRONMENT; HUMANS; LIFE STYLE; MENTAL DISORDERS; METABOLIC SYNDROME X; METFORMIN; POLYMORPHISM, GENETIC; PSYCHOTROPIC DRUGS; RISK; STRESS, PSYCHOLOGICAL;

EID: 79953090058     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2010.0053     Document Type: Review

References (92)

1. Linchtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Holtman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: A population-based study. Lancet 2009;373:234-239.
2. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bi-polar disorder and schizophrenia treated with second gen-eration antipsychotics. Bipolar Disord 2008;10:788-797.
3. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: Why the excess cardiovascular risk in bipolar disorder? Curr Psychiatry Rep 2009;11:475-480.
4. Moreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Mart́nez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 2010;12:172-184.
5. Babić D, Maslov B, Martinac M, Nikolić K, Uzun S, Kozumplik O. Bipolar disorder and metabolic syndrome: comorbidity or side effects of treatment of bipolar disorder. Psychiatr Danub 2010;22:75-78.
6. Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010 (E pub May 4).
7. Brown LC, Majumdar SR, Newman SC, Johnson JA. History of depression increases the risk of type 2 diabetes in younger adults. Diabetes Care 2005;28:1063-1067 (Pubitemid 40616614)
8. Goldbacher EM, Bromberger J, Mathews KA. Lifetime his-tory of major depression predicts the development of met-abolic syndrome in middle aged women. Psychosom Med 2009;71:266-272.
9. Carroll D, Phillips AC, Thomas GN, Gale CR, Deary J, Batty GD. Generalized anxiety disorder is associated with meta-bolic syndrome in the Vietnam experience study. Biol Psy-chiatry 2009;66:91-93.
10. Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fab-ricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE. Obesity among those with mental disorders: A National Institute of Mental Health meeting report. Am J Prev Med 2009;36:341-350.
11. Stahl SM, Mignon L, Meyer JM. Which comes first: Atypical antipsychotic treatment or cardiometabolic risk? Acta Psy-chiatr Scand 2009;119:171-179.
12. Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA, CAFE Investigators. Metabolic profiles of second-generation antipsychotics in early psy-chosis: FIndings from the CAFE study. Schizophr Res 2009; 111:9-16.
13. Zimmerman U, Kraus T, Himmerich H, Skuld A, Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychitric Res 2003;37:193-220. (Pubitemid 36321747)
14. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotro-pic drugs: selective clinical review. CNS Drugs 2009;23: 1003-1021.
15. Kisely S, Cox M, Campbell LA, Cooke C, Gardner D. An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. Can J Psychiatry 2009;54:269-274.
16. Howland RH Pharmacotherapy for psychotropic drug-related weight gain. J Psychosoc Nurs Ment Health Serv 2008; 46:15-18.
17. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 2010 (Epub June 8).
18. Zeman M, Jirak R, Jachymova M, Vecka M, Tvrzicka E, Zak A. Leptin, adiponectin, leptin to adiponectin ratio and in-sulin resistance in depressive women. Neuro Endocrinol Lett 2009;30:387-395.
19. Takeuchi T, Nakao M, Nomura K, Inoue M, Tsurugano S, Shinozaki Y, Yano E. Association of the metabolic syndrome with depression and anxiety in Japanese men: A 1-year co-hort study. Diabetes Metab Res Rev 2009;25:762-767.
20. Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O, Akin F. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizo-phrenia. DNA Cell Biol 2009;28:515-519.
21. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psy-chosis. J Clin Psychiatry 2009;70:997-1000.
22. Al-Nozha M, Al-Khadra A, Arafah MR, Al-Maatouq MA, Khalil MZ, Khan NB, Al-Mazrou YY, Al-Marzouki K, Al-Harthi SS, Abdullah M, Al-Shahid MS, Al-Mobeireek A, Nouh MS. Metabolic syndrome in Saudi Arabia. Saudi Med J 2005;26:1918-1925. (Pubitemid 43180350)
23. Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, Jousilahti P. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 2003;26:1781-1785. (Pubitemid 36929119)
24. Newcomer JW. Metabolic syndrome and mental illness. Am J Manag Care 2007;13(Suppl 7):S170-S177 (Pubitemid 350231678)
25. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: A review. World Psychiatry 2009;8:15-22.
26. Meyer JM, Stahl SM. The metabolic syndrome and schizo-phrenia. Acta Psychiatr Scand 2009;119:4-14.
27. Kohen D. Diabetes mellitus and schizophrenia: Historical perspective. Br J Psychiatry 2004;184(Suppl 47):s64-s66. (Pubitemid 38482545)
28. Lambert TJR. The medical care of people with psychosis. Med J Australia 2009;190:171-172.
29. Dinan TG. Stress and the genesis of diabetes mellitus in schizophrenia. Br J Psychiatry 2004;184(Suppl 47):s72-s75. (Pubitemid 38482547)
30. Walker EF, Diforio D: Schizophrenia. A neural diathesis-stress model. Psychol Rev 1997;104:667-685.
31. Walker E, Mittal V, Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 2008;4:189-216. (Pubitemid 351668616)
32. Jones SR, Fernyhough C A new look at the neural diathesis-stress model of schizophrenia: The primacy of social-evaluative and uncontrollable situations. Schizophr Bull 2007; 33:1171-1177 (Pubitemid 47347907)
33. Yevtushenko OO, Cooper SJ, O'Neill R, Doherty JK, Woodside JV, Reynolds GP. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treat-ment on metabolic disturbances in patients with schizo-phrenia. Br J Psychiatry 2008;192:424-428. (Pubitemid 351809894)
34. Templeman LA, Reynolds GP, Arranz B, San L. Poly-morphisms of the 5-HT2C receptor and leptin genes are as-sociated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharma-cogenet Genomics 2005;15:195-200. (Pubitemid 40569890)
35. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on nega-tive and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006;163:1826-1829. (Pubitemid 44522494)
36. Mulder H, Cohen D, Schefer H, de Weid CG, Arends J, Wilmink FW, Franke B, Egberts AC HTR2C gene poly-morphisms and metabolic syndrome in patients with schizophrenia. J Clin Psychopharm 2009;29:16-20.
37. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
38. Marder SR, Essock SM, Miller AL. Physical health moni-toring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349. (Pubitemid 38989085)
39. De Nayer A, De Hert M, Scheen A, Van Gaal L, Peuskens J. Conference report: Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 2007;33: 197-202. (Pubitemid 46787708)
40. De Hert M, van Eyck D, De Nayer A. Metabolic abnormal-ities associated with second generation antipsychotics: Fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychophramacol 2006;21(Suppl 2): s11-s15. (Pubitemid 43740324)
41. Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista EA. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction dur-ing olanzapine administration: A multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007;93:99-108. (Pubitemid 46839067)
42. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. Schizophrenia Patient Outcomes Research Team (PORT), The 2009 schizophrenia PORT psychopharmaco- logical treatment recommendations and summary state-ments. Schizophr Bull 2010;36:71-93.
43. Wilffert B, Zaal R, Brouwers JR. Pharmacogenetics as a tool in the therapy of schizophrenia. Pharm World Sci 2005; 27:20-30. (Pubitemid 40362673)
44. Arranz MJ, de Leon J. Pharmacogenetics and pharmacoge-nomics of schizophrenia: A review of last decade of research. Mol Psychiatry 2007;12:707-747 (Pubitemid 47172693)
45. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W, Mors O, Placentino A, Rietschel M, Souery D, Zagar T, Czerski PM, Jerman B, Larsen ER, Schulze TG, Zobel A, Cohen-Woods S, Pirlo K, Butler AW, Muglia P, Barnes MR, Lathrop M, Farmer A, Breen G, Aitchison KJ, Craig I, Lewis CM, McGuffin P. Genome-Wide Pharmacogenetics of Anti-depressant Response in the GENDEP Project. Am J Psychiatry 2010 (Epub April).
46. Rozanski A, Blumenthal JA, Davidson KW, Saab PG, Kub-zansky L. The epidemiology, pathophysiology, and man-agement of psychosocial risk factors in cardiac practice: The emerging field of behavioral cardiology. J Am Coll Cardiol 2005;45:637-651. (Pubitemid 40278960)
47. Rozanski A, Kubzansky LD. Psychologic functioning and physical health: A paradigm of flexibility. Psychosom Med 2005;67(Suppl 1):S47-S53. (Pubitemid 40721033)
48. Rozanski A. Integrating psychologic approaches into the behavioral management of cardiac patients. Psychosom Med 2005;6(Suppl 1):S67-S73. (Pubitemid 40721037)
49. Kubzansky LD, Davidson KW, Rozanski A. The clinical impact of negative psychological states: expanding the spectrum of risk for coronary artery disease Psychosom Med 2005;67(Suppl 1):s10-s14. (Pubitemid 40721025)
50. Dagogo-Jack S, Egbuonu N, Edeoga C Principles and practice of nonpharmacological interventions to reduce car-diometabolic risk. Med Princ Pract 2010;19:167-175.
51. Spanier PA, Marshall SJ, Faulkner GE. Tackling the obesity pandemic: A call for sedentary behaviour research. Can J Public Health 2006;97:255-257 (Pubitemid 44043641)
52. Thakore JH. Metabolic disturbance in first-episode schizo-phrenia. Br J Psychiatry 2004;184(Suppl. 47):s76-s79.
53. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose and elevation of cortisol in drug-näve first episode schizo-phrenia. Am J Psychiatry 2003;160:284-289.
54. Ryan MCM, Sharifi N, Condren R. Evidence of basal pitui-tary-adrenal overactivity in first episode, drug-näve pa-tients with schizophrenia. Psychoneuroendocrinology 2004;29: 1065-1070. (Pubitemid 38833534)
55. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry 2006;51:382-386. (Pubitemid 43854472)
56. van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Ve-nema HW, de Haan L, Becker H, van Amelsvoort T, Ack-ermans MT, Fliers E, Serlie MJ, Sauerwein HP. Hepatic insulin resistance in antipsychotic naive schizophrenic pa-tients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008;93:572-577. (Pubitemid 351240833)
57. Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR. Asso-ciations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects. Clin Chem Lab Med 2007;45:1229-1231.
58. Wolkowitz OM, Epel ES, Reus VI, Mellon SH. Depression gets old fast: Do stress and depression accelerate cell aging? Depress Anxiety 2010;27:327-338.
59. Brown LC, Majumdar S R, Newman S C, Johnson JA. Type 2 diabetes does not increase risk of depression. CMAJ 2006;175:42-46. (Pubitemid 44065190)
60. O'Connor PJ, Cram AL, Rush WA, Hanson AM, Fischer LR, Kluznik JC Does diabetes double the risk of depression? Am Fam Med 2009;7:328-335.
61. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009;374:620-627.
62. Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of di-abetes mellitus. Am J Psychiatry 2009;166:591-598.
63. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH. The effect of antidepressants on lipid homeostasis: A cardiac safety concern? Expert Opin Drug Saf 2006;5:523-537. (Pubitemid 44468450)
64. Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Dveaugh-Geiss A, Krebs EE, Lohr KN. Comparative risks for harms of second generation antidepressants: A systematic review and meta-analysis. Drug Saf 2008;31:851-865.
65. Newcomer JW. Second generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005;19:1-93. (Pubitemid 40677047)
66. Gorczynski P, Faulkner G Exercise therapy for schizophre-nia. Cochrane Database Syst Rev 2010;5:CD004412.
67. Thorndike AN, Rigotti NA. A tragic triad: Coronary artery disease, nicotine addiction, and depression. Curr Opin Car-diol 2009;24:447-453.
68. Faulkner GE, Gorczynski PF, Cohn TA. Psychiatric illness and obesity: Recognizing the "obesogenic" nature of an in-patient psychiatric setting. Psychiatr Serv 2009;60:538-541.
69. Czobor P, Volavka J, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA. Anti-psychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-251. (Pubitemid 34546838)
70. Fleischhaker C, Schultz E, Remschmidt H. Biogenic amines as predictors of response to clozapine treatment in early onset schizophrenia. J Psychiatr Res 1998;32:325-333. (Pubitemid 28410124)
71. Akanji AO, Ohaeri JU, Al-Shammri SN, Fatania HR Apoli-poprotein E polymorphism and clinical disease phenotypes in Arab patients with schizophrenia. Neuropsychobiology 2009;60:67-72.
72. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J. Schizophrenia Patient Outcomes Research Team (PORT), The 2009 schizophrenia PORT psy-chosocial treatment recommendations and summary state-ments. Schizophr Bull 2010;36:48-70.
73. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349. (Pubitemid 38989085)
74. Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra J L, Azorin JM. Avec le soutien institutionnel du laboratoire Lilly, Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale 2009;35:330-339.
75. Holt R, Abdelrahman T, Hirsch M, Dhesi Z, George T, Blincoe T Peveler R The prevalence of undiagnosed meta-bolic abnormalities in people with serious mental illness. J Psychopharmacol 2009;24:867-873.
76. Morrato E.H, Cuffel B, Newcomer J.W, Lombardo I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of com-mercially insured patients. J Clin Psychopharmacol 2009;29: 26-32.
77. Brunero S, Lamont S, Fairbrother G Prevalence and pre-dictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 2009;23:261-268.
78. Richardson CR, Faulkner G, McDevitt J, Skrinar GS, Hutchinson DS, Piette JD. Integrating physical activity into mental health services for persons with serious mental ill-ness. Psychiatr Serv 2005;56:324-331. (Pubitemid 40333566)
79. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Co-chrane Database Syst Rev 2010;3:CD006654.
80. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, Leucht S. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;4:CD006627.
81. Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M. Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies. CNS Spectr 2009;14: 478-486.
82. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: Meta-analysis. Br J Psychiatry 2010;196: 434-439.
83. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70: 1041-1050.
84. Ehret M, Goethe J, Lanosa M, Coleman CI. The effect of metformin on anthropometrics and insulin resistance in pa-tients receiving antipsychotic agents: A meta-analysis. J Clin Psychiatry 2010, DOI:10.4088/JCP.09m05274.yel.
85. Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lie-berman JA. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 2008;103:104-109.
86. Kemp DE, Calabrese JR, Tran QV, Pikalov A, Eudicone JM, Baker RA. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: A post hoc analysis of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010(Epub May 4).
87. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009;29:165-169.
88. Blouin M, Binet M, Bouchard RH, Roy MA, Després JP, Al-méras N. Improvement of metabolic risk profile under sec-ond-generation antipsychotics: A pilot intervention study. Can J Psychiatry 2009;54:275-279.
89. Small G. Effects of a 14-day healthy life style program on cognition and brain function. In: Measuring the Immeasurable: The Scientific Casefor Spirituality. Boulder, Colorado: Sounds True, 2008, pp 35-46.
90. Bobes J, Alegŕa AA, Saiz-Gonzalez MD, Barber I, Pérez JL, Saiz-Ruiz J. Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. Eur Psychiatry 2010 (Epub June).
91. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or halo-peridol. Schizophr Res 2009;110:95-102.
92. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in pa-tients with schizophrenia. J Clin Psychiatry 2009;70:318-325.